SG Americas Securities LLC Buys 10,077 Shares of CG Oncology, Inc. $CGON

SG Americas Securities LLC boosted its stake in shares of CG Oncology, Inc. (NASDAQ:CGON) by 92.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 20,949 shares of the company’s stock after purchasing an additional 10,077 shares during the period. SG Americas Securities LLC’s holdings in CG Oncology were worth $870,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in CGON. Wellington Management Group LLP boosted its holdings in CG Oncology by 190.3% in the third quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock worth $222,055,000 after acquiring an additional 3,613,885 shares in the last quarter. Bank of America Corp DE raised its position in shares of CG Oncology by 409.9% in the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock worth $45,156,000 after purchasing an additional 1,396,170 shares during the last quarter. Vanguard Group Inc. boosted its stake in CG Oncology by 11.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock worth $264,933,000 after purchasing an additional 670,770 shares in the last quarter. Millennium Management LLC grew its position in CG Oncology by 139.4% during the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after purchasing an additional 347,055 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in CG Oncology by 15.0% during the 2nd quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock valued at $56,270,000 after purchasing an additional 281,637 shares in the last quarter. 26.56% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Morgan Stanley set a $93.00 target price on shares of CG Oncology in a report on Friday, January 9th. The Goldman Sachs Group restated a “buy” rating and issued a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research report on Wednesday, January 21st. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Royal Bank Of Canada boosted their price target on CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, CG Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.67.

CG Oncology Stock Down 0.5%

CGON opened at $68.56 on Friday. The stock has a market capitalization of $5.79 billion, a price-to-earnings ratio of -33.12 and a beta of 0.70. The firm has a 50 day moving average price of $60.33 and a 200-day moving average price of $49.16. CG Oncology, Inc. has a twelve month low of $16.17 and a twelve month high of $71.90.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.10. The company had revenue of $2.32 million during the quarter. As a group, analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Insider Activity

In other news, Director James Mulay sold 1,964 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $63.50, for a total value of $124,714.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.40% of the stock is currently owned by company insiders.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.